Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
Spero Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: SPRO), announced that Dr. Ankit Mahadevia will present at the virtual Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 10:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spero Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: SPRO), announced that Dr. Ankit Mahadevia will present at the virtual Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 10:30 AM ET. The presentation will cover advancements in treatments for multi-drug resistant infections and rare diseases, including the lead product candidate, tebipenem HBr, aimed at urinary tract infections. Investors can register for the event via a provided link, and a replay will be available on Spero's website after the presentation.
Details
News Market Reaction – SPRO
The recorded move for SPRO in the trading session of this news was +1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 – 14, 2021. Details for the presentation are as follows:
Ladenburg Thalmann Healthcare Conference
Presentation Date & Time: Tuesday, July 13 at 10:30 AM ET
Webcast Link: Register Here
A webcast of the presentation may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. A replay of the presentation will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-430-7577
Media Contact:
media@sperotherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.